Oral BGE-102

DRUG2 trials

Sponsors

BioAge Labs, Inc.

Conditions

Diabetic Macular Edema (DME)Obesity and Cardiovascular Risk

Phase 2

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Active, not recruitingNCT07656727

BioAge Labs, Inc.Obesity and Cardiovascular Risk

Start: 2026-06-11End: 2026-12-01Target: 160Updated: 2026-09-10

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

RecruitingNCT07812090

BioAge Labs, Inc.Diabetic Macular Edema (DME)

Start: 2026-08-21End: 2027-12-01Target: 180Updated: 2026-09-10